Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
A technology for celecoxib and capsules, applied in the field of capsules containing celecoxib, which can solve the problems of high energy consumption, poor capsule quality uniformity and stability, and high equipment requirements
Active Publication Date: 2014-08-20
SICHUAN GOWELL PHARMA
View PDF7 Cites 10 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0010] One of the problems to be solved in the present invention is that the celecoxib bulk drug synthesized cannot be directly used in the preparation of the existing celecoxib capsules, and the directly synthesized particle diameter D 90 The celecoxib API with a size of 20 μm to 50 μm is micronized to D 90 Only when the dissolution rate is less than 18 μm can a preparation with a dissolution rate meet the requirements be obtained; however, the micronization process requires high equipment, consumes a lot of energy and costs, and at the same time, the celecoxib particles after micronization are easy to aggregate into agglomerates, which is easy to dissolve when filling capsules. Sticky punch occurs, unable to fill smoothly
At the same time, the prior art also has technical problems such as poor capsule quality uniformity and stability without micronization
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0124] Prescription Prescription amount % by weight
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Property
Measurement
Unit
particle diameter
aaaaa
aaaaa
particle diameter
aaaaa
aaaaa
particle diameter
aaaaa
aaaaa
Login to view more
Abstract
The invention relates to a celecoxib-containing capsule, which contains 40wt%-70wt% of celecoxib, 22wt%-50wt% of a water-soluble filler, 0.5wt%-25wt% of low substituted hydroxypropyl cellulose, and 0.5wt%-10wt% of sodium dodecyl sulfate. The celecoxib capsule with a prescription provided by the invention has no special requirement for the particle size of celecoxib, the celecoxib bulk drug directly synthesized by a conventional synthesis method can be taken as a preparation raw material, and no special treatment is needed. The preparation process is simple, the product quality is uniform and stable, and has effective bioavailability.
Description
technical field [0001] The invention relates to pharmaceutical preparations, in particular to a capsule containing celecoxib. Background technique [0002] Celecoxib (Celecoxib, 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benzenesulfonamide) is produced by G.D. The developed coxib non-steroidal anti-inflammatory drugs (NSAIDs) are as effective as traditional NSAIDs in terms of analgesia, anti-inflammatory and antipyretic, but due to their highly selective and specific inhibition of COX-2 It only reduces the synthesis of inflammatory prostaglandins without affecting the synthesis of physiological prostaglandins, thus reducing gastrointestinal damage, and its digestive tract safety is better than that of traditional NSAIDs. [0003] Celecoxib was launched in the United States on December 31, 1998, and is now on the market in 72 countries (regions) including North America, South America, Asia, and Europe. On August 4, 2000, my country approved the import of cele...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more